肿瘤与神经PET/CT检查的有效剂量估算
该研究回顾性评估了210例患者接受多种PET放射性药物(18FDG、11C-CHOL、18FDOPA、11C-MET、18F-florbetapir)进行躯干、全身、头颈肿瘤和脑部PET/CT检查的有效剂量。结果显示体部方案总有效剂量为13.5–20.0 mSv,CT贡献占62%–77%;脑部方案为4.6–9.1 mSv,CT贡献占11%–26%。
要点
- 体部PET/CT方案总有效剂量为13.5–20.0 mSv,CT是主要贡献者(62%–77%)。
- 脑部PET/CT方案总有效剂量为4.6–9.1 mSv,PET放射性药物是主要贡献者。
- 18FDG PET/CT中扫描长度和手臂位置变化导致CT有效剂量显著差异(p < 0.01)。
核心结论
- 不同放射性药物的体部和脑部PET/CT方案平均有效剂量范围为4.6–20.0 mSv。
研究设计与样本
- 回顾性评估210例患者的PET/CT检查,包括躯干(n = 123)、全身(n = 36)、头颈肿瘤(n = 10)和脑部(n = 41)方案。
- 使用的放射性药物包括18FDG(n = 170)、11C-CHOL(n = 10)、18FDOPA(n = 10)、11C-MET(n = 10)和18F-florbetapir(n = 10)。
- 有效剂量通过放射性药物活度和CT剂量长度乘积的转换因子计算。
主要发现
- 躯干-11C-CHOL、躯干-18FDG、全身-18FDG和头颈肿瘤-18FDG方案的总有效剂量(均值±标准差)分别为13.5 ± 2.2、16.5 ± 4.5、20.0 ± 5.6和15.4 ± 2.8 mSv,其中CT贡献分别占77%、62%、69%和63%。
- 18FDG、18FDOPA、11C-MET和18F-florbetapir脑部PET/CT的有效剂量(均值±标准差)分别为6.4 ± 0.6、4.6 ± 0.4、5.2 ± 0.5和9.1 ± 0.4 mSv,CT贡献分别占11%、14%、23%和26%。
- 在18FDG PET/CT中,扫描长度和手臂位置的变化导致CT有效剂量显著差异(p < 0.01)。
- 对于双时间点显像,延迟扫描的CT有效剂量(均值±标准差)为3.8 ± 1.5 mSv。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The aim of this study was to retrospectively evaluate the patient effective dose (ED) for different PET/CT procedures performed with a variety of PET radiopharmaceutical compounds. PET/CT studies of 210 patients were reviewed including Torso (n = 123), Whole body (WB) (n = 36), Head and Neck Tumor (HNT) (n = 10), and Brain (n = 41) protocols with 18FDG (n = 170), 11C-CHOL (n = 10), 18FDOPA (n = 10), 11C-MET (n = 10), and 18F-florbetapir (n = 10). ED was calculated using conversion factors applied to the radiotracer activity and to the CT dose-length product. RESULTS: Total ED (mean ± SD) for Torso-11C-CHOL, Torso-18FDG, WB-18FDG, and HNT-18FDG protocols were 13.5 ± 2.2, 16.5 ± 4.5, 20.0 ± 5.6, and 15.4 ± 2.8 mSv, respectively, where CT represented 77, 62, 69, and 63% of the protocol ED, respectively. For 18FDG, 18FDOPA, 11C-MET, and 18F-florbetapir brain PET/CT studies, ED values (mean ± SD) were 6.4 ± 0.6, 4.6 ± 0.4, 5.2 ± 0.5, and 9.1 ± 0.4 mSv, respectively, and the corresponding CT contributions were 11, 14, 23, and 26%, respectively. In 18FDG PET/CT, variations in scan length and arm position produced significant differences in CT ED (p < 0.01). For dual-time-point imaging, the CT ED (mean ± SD) for the delayed scan was 3.8 ± 1.5 mSv. CONCLUSIONS: The mean ED for body and brain PET/CT protocols with different radiopharmaceuticals ranged between 4.6 and 20.0 mSv. The major contributor to total ED for body protocols is CT, whereas for brain studies, it is the PET radiopharmaceutical.
引用
- Martí-Climent JM, Prieto E, Morán V, et al. Effective dose estimation for oncological and neurological PET/CT procedures. EJNMMI Res. 2017. PMID: 28439843. doi:10.1186/s13550-017-0272-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。